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Genome-wide association study identiﬁes multiple
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Ewing sarcoma (EWS) is a pediatric cancer characterized by the EWSR1-FLI1 fusion. We
performed a genome-wide association study of 733 EWS cases and 1346 unaffected indi-
viduals of European ancestry. Our study replicates previously reported susceptibility loci at
1p36.22, 10q21.3 and 15q15.1, and identiﬁes new loci at 6p25.1, 20p11.22 and 20p11.23. Effect
estimates exhibit odds ratios in excess of 1.7, which is high for cancer GWAS, and striking in
light of the rarity of EWS cases in familial cancer syndromes. Expression quantitative trait
locus (eQTL) analyses identify candidate genes at 6p25.1 (RREB1) and 20p11.23 (KIZ). The
20p11.22 locus is near NKX2-2, a highly overexpressed gene in EWS. Interestingly, most loci
reside near GGAA repeat sequences and may disrupt binding of the EWSR1-FLI1 fusion
protein. The high locus to case discovery ratio from 733 EWS cases suggests a genetic
architecture in which moderate risk SNPs constitute a signiﬁcant fraction of risk.
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Ewing sarcoma (EWS) is a rare, aggressive pediatric bone orsoft-tissue tumor that normally occurs during the seconddecade of life1 and likely arises from neural crest- or
mesoderm-derived mesenchymal stem cells2,3. A translocation
between EWSR1 (22q12) and a member of the ETS transcription
factor family, FLI1 (11q24), in ~85% of cases, is pathognomonic
of EWS and provides a distinct and well-deﬁned disease pheno-
type for genomic characterization4–6. The translocation results in
an aberrant transcription factor that binds to an ETS-like motif or
to GGAA microsatellites and promotes cell transformation
through deregulation of target genes responsible for cell cycle
control, cell death and migration6–9. Aside from EWSR1-ETS
translocations, there are few other recurrent somatic alterations
observed in EWS10–12.
In 1970, Fraumeni reported a striking disparity in EWS inci-
dence across human populations13, suggesting an intriguing
contribution of germline variation to EWS susceptibility14. EWS
is predominantly observed in Europeans with an estimated inci-
dence of ~1.5 cases per 106 children and young adults15. The
estimated incidence in Asian and African populations is sub-
stantially lower with annual rates of 0.8 and 0.2 cases per 106
children, respectively, implying genetic variants speciﬁc to Eur-
opean ancestry could inﬂuence EWS risk13,15–18. Despite the
rarity of EWS, infrequent and anecdotal instances of familial
clustering of EWS in siblings or cousins have also been reported,
further suggesting an important genetic component to EWS19,20.
However, it is notable that EWS is rarely observed in the
approximately 120 cancer predisposition syndromes described to
date21.
Our previous genome-wide association study (GWAS) identi-
ﬁed susceptibility loci at 1p36.22, 10q21 and 15q1522. A follow-up
functional study of the 10q21 region localized the association
signal to variation in a GGAA microsatellite that, when bound by
EWSR1-FLI1, functions as an active regulatory element of
EGR223. Speciﬁcally, the A risk allele connected adjacent GGAA
repeats by converting an interspaced GGAT motif into a GGAA
motif, increasing the number of consecutive GGAA motifs and
thus, magnifying the EWSR1-FLI1-dependent enhancer activity.
Interestingly, EGR2 knock down inhibits cell proliferation, clo-
nogenicity and tumor growth of EWS cells23. Collectively, these
ﬁndings indicate that germline variation predisposes to EWS risk
and can interact with somatically acquired EWSR1-ETS fusion
proteins to drive carcinogenesis of EWS.
In this report, we perform a GWAS of EWS that combines 401
cases and 682 controls from the previously published EWS
GWAS22 with four new sample sets for a combined total of 733
EWS cases and 1346 unaffected individuals. In total, we investi-
gate EWS associations across 6,876,682 SNPs (genotyped plus
high quality imputed) with an overall meta-analysis lambda value
of 1.035 (Supplementary Figure 1). We replicate prior associa-
tions at 1p36.22, 10q21.3 and 15q15.1 and identify evidence for
three new susceptibility loci: 6p25.1, 20p11.22 and 20p11.23
(Table 1, Fig. 1, Supplementary Table 1, Supplementary Fig-
ures 2–3).
Table 1 Magnitude and strength of association for previously published and new EWS susceptibility loci
Region Top SNP Ref Risk Odds Ratio 95% Conﬁdence Interval Assoc P-value Het P-value
1p36.22 rs113663169 C T 2.05 1.71 2.45 4.32E-15 0.58
6p25.1 rs7742053 C A 1.80 1.48 2.18 2.78E-09 0.12
10q21.3 rs10822056 C T 1.76 1.54 2.02 1.92E-16 0.45
15q15.1 rs2412476 C T 1.73 1.48 2.01 1.45E-12 0.93
20p11.22 rs6047482 T A 1.74 1.49 2.04 2.55E-12 0.90
20p11.23 rs6106336 T G 1.74 1.43 2.12 2.33E-08 0.16
Ref reference allele, Risk risk allele, RAF risk allele frequency (CEU), Assoc P-value Meta-analysis combined association P-value for GWAS discovery set, Het P-value P-value from test of heterogeneity
for GWAS discovery set
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Fig. 1 Manhattan plot of meta-analysis –log10 P-values for the association of each SNP with EWS risk. Association -log10 p-values for each tested genetic
variant are plotted. Chromosomes are plotted sequentially across the x-axis with the scale proportional to chromosomal size. Colors are used to visualize
differences in chromosome. The dotted line indicates genome-wide signiﬁcance (P<5×10-8)
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Results and discussion
Methods Summary. Our analysis was restricted to individuals of
>80% estimated European ancestry based on a principal com-
ponent analysis of population substructure. EWS cases were
conﬁrmed by medical record review, which included checking for
the presence of EWSR1-ETS fusions when data was available.
Principal component matching was performed to select a
genetically homogeneous set of adult controls who were cancer-
free as of age 50 for each EWS case. Sample and SNP quality
control exclusions were carried out to ensure unrelated, high
quality samples for association analysis with accurate genotype
assays. Missing genotypes were imputed using 1000 Genomes
Phase 3 haplotypes as a reference24. We combined results across
studies using a ﬁxed effects meta-analysis. Variants with minor
allele frequencies <5% or signiﬁcant evidence for heterogeneity
were ﬁltered from the ﬁnal results. A more detailed description of
our experimental methods and analysis technique is available in
Methods.
Replication of prior EWS GWAS. Our analysis provided strong
replication of three previously discovered EWS susceptibility loci22
and aided in reﬁning the association signals. We observed
rs113663169 as the most signiﬁcant variant tagging the 1p36.22
locus (OR= 2.05, 95% CI= 1.71–2.45, P-valuemeta= 4.32×10−15).
This variant is in high linkage disequilibrium (LD) with the original
reported variant rs9430161 (R2CEU= 0.97, D′CEU= 1.00;25 OR=
2.03, 95% CI= 1.70–2.42, P-valueassoc= 6.3×10−15)22 and is located
upstream of TARDBP, a transcriptional repressor that shares
structural similarities with EWSR1 and binds RNA regulatory ele-
ments. At the 10q21 locus, we observed rs10822056 with the
strongest association (OR= 1.76, 95% CI= 1.54–2.02, P-valuemeta
= 1.92×10−16). This variant is correlated with the reported variant
from the original GWAS, rs224278 (R2CEU= 0.52, D′CEU= 0.92;25
OR= 1.71, 95% CI= 1.49–1.96, P-valueassoc= 6.9×10−15)22, as well
as the putatively functional variant, rs79965208 (R2CEU= 0.24, D
′CEU= 0.57;25 OR= 1.42, 95% CI= 1.24–1.63, P-valueassoc=
5.3×10−7)23. Interestingly, as indicated previously23, the conditional
analysis at 10q21.3 suggests evidence for a residual independent
signal in this region, although larger EWS GWAS are needed to
conﬁrm the presence of multiple independent signals. Finally, at
15q15.1 we observed rs2412476, a tagging variant strongly asso-
ciated with EWS (OR= 1.73, 95% CI= 1.48–2.01, P-valuemeta=
1.45×10−12). This variant is in moderate LD with rs4924410 from
the original GWAS (R2CEU= 0.18, D′CEU= 1.0025; OR= 1.62, 95%
CI= 1.41–1.86, P-valueassoc= 5.4×10−12)22 and is located near
several genes including BMF, BUB1B and PAK6.
Newly identiﬁed EWS susceptibility loci. Our analysis identiﬁed
suggestive evidence for novel genomic associations (P-valuemeta <
5 × 10−7) in four genomic regions (Table 1, Supplementary
Table 1): 6p25.1, 8q24.23, and 20p11.22 and 20p11.23. To vali-
date signals from imputed variants in these regions, we performed
allele-speciﬁc TaqMan PCR for a subset of 335 GWAS samples
on the following variants: rs7744366 (6p25.1), rs7832583
(8q24.23), rs12106193 (20p11.22) and rs6106336 (20p11.23). All
PCR-validated genotypes had over 93–99% concordance with
imputed genotypes indicating high accuracy of imputation in
these regions (Supplementary Table 2). Additionally, these signals
were replicated in two independent series of EWS cases and
controls: a European set from the Institute Curie containing of
480 EWS cases and 576 controls22, and a German set from LMU
Munich containing 177 EWS cases and 3502 controls. All com-
bined association P-values (GWAS discovery+independent
replication sets) were below genome-wide signiﬁcance levels (P-
valuemeta < 5 × 10−8, Supplementary Table 1, Supplementary
Figures 2–5) except for the 8q24.23 locus (P-valuemeta= 1.44 ×
10−7). The 6p25.2 and 20p11.22 signals were independently
replicated in both German and European replication sets; how-
ever, the 8q24.23 signal was only signiﬁcant in the European set
(P-valueassoc= 0.007) and the 20p11.23 signal was only replicated
in the German set (P-valueassoc= 0.036).
EWS susceptibility locus at 6p25. We identiﬁed a new locus on
6p25.1 tagged by rs7742053 (OR= 1.80, 95% CI= 1.48–2.18, P-
valuemeta= 2.78×10−9) with the A allele being the risk associated
allele (Supplementary Table 3). The marker variant rs7742053 is
telomeric to RREB1, SSR1 and CAGE1. Expression quantitative
trait locus (eQTL) analysis using rs1286037, a correlated surro-
gate for rs7742053 (R2CEU= 0.49, D′CEU= 1.00)25, identiﬁed
allele speciﬁc expression differences in RREB1, with the risk A
allele of rs7742053 corresponding to increased levels of RREB1
expression (P-valueWald= 0.01, Table 2). RREB1 encodes the RAS
responsive element (RRE) binding protein 1, a zinc-ﬁnger tran-
scription factor that binds to RRE in gene promoters26. RREB1 is
expressed in EWS tumors at higher levels than other pediatric
sarcomas (Supplementary Figure 6), suggesting regulation of
RREB1 may be particularly important for EWS. In addition, the
6p25.1 locus shows evidence for an interaction between germline
Table 2 Functional associations for newly identiﬁed EWS susceptibility loci
Locus SNP Risk Allele Gene eQTL Proxy SNP Proxy R2/D′ eQTL P-value eQTL Direction EWSR1-FLI1 knock
down
6p25.1 rs7742053 A CAGE1 rs1286037 0.49/1.00 0.939 —
LY86 rs1286037 0.49/1.00 0.727 —
LY86-AS1 rs1286037 0.49/1.00 0.487 —
RREB1 rs1286037 0.49/1.00 0.010 ↑ ↓
SSR1 rs1286037 0.49/1.00 0.630 —
8q24.23 rs7832583 C none — — — —
20p11.22 rs6047482 A KIZ rs6137387 0.60/1.00 0.478 — ↓
NKX2-2 rs6137387 0.60/1.00 0.127 — ↓
PAX1 rs6137387 0.60/1.00 0.489 —
XRN2 rs6137387 0.60/1.00 0.277 —
20p11.23 rs6106336 G KIZ rs6047241 1.00/1.00 0.014 ↑ ↓
NKX2-2 rs6047241 1.00/1.00 0.359 — ↓
XRN2 rs6047241 1.00/1.00 0.260 —
Risk allele is the allele associated with increased EWS risk. eQTL P-value is from a Wald test of the genotype beta value. eQTL direction is the effect the risk allele has on quantitated gene expression.
EWSR1-FLI1 knock down indicates the effect of EWSR1-FLI1 knock down on relative gene expression. The up arrow (↑) indicates increased expression and the down arrow (↓) indicates decreased
expression
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variation and EWSR1-FLI1 fusion proteins. ChIP-seq of acety-
lated H3K27 (H3K27ac) indicates an area of open chromatin that
spans a polymorphic GGAA microsatellite near rs7742053
(Supplementary Figure 7-8, Supplementary Tables 4-5). ChIP-seq
analysis of EWSR1-FLI1 in the A673 and TC-71 EWS cell lines
conﬁrm EWSR1-FLI1 binding to this GGAA microsatellite at
6p25.1. Further, knock down of EWSR1-FLI1 in xenografts
derived from the A673/TR/shEF1 EWS cell line results in strong
downregulation of RREB1 in vivo (Supplementary Figure 9).
Several variants correlated with rs7742053 are in contiguity with
the GGAA repeat and may be candidate functional variants that
disrupt EWSR1-FLI1 binding (Supplementary Table 5). One such
variant, rs10541084, a -/GAAG indel is located at the telomeric
end of the nearest GGAA microsatellite, is in LD with rs7742053
(R2CEU= 0.15, D′CEU= 0.92)25, and is nominally associated with
EWS (OR= 1.20, 95% CI= 1.04–1.37, P-valuemeta= 0.01).
Interestingly, the rs7742053 risk A allele is correlated with the
rs10541084 GAAG allele which is more common in Europeans,
extends the microsatellite GGAA repeat sequence, and could
enhance binding of EWSR1-FLI1. This evidence suggests that a
similar mechanism as in the 10q21 locus23 may be acting at the
6p25.1 locus in which variation of a GGAA repeat affects
EWSR1-FLI1 binding leading to altered expression of RREB1 or
an alternative nearby gene. Further functional work at 6p25.1 is
required to clarify which variants are functionally responsible for
the susceptibility signal.
EWS susceptibility locus at 20p11. We identiﬁed an association
signal spanning chromosome 20p11.22-23. The strongest asso-
ciation signal was on 20p11.22 tagged by rs6047482 (OR= 1.74,
95% CI= 1.49–2.04, P-valuemeta= 2.55×10−12). The A allele is
the risk allele with a higher frequency observed in 1000 Genome
Europeans than in Africans (Supplementary Table 3). While no
statistically signiﬁcant eQTL was observed between this locus and
nearby genes (Table 2), the nearest transcript, NKX2-2, is of high
interest; NKX2-2, NK2 homeobox 2, encodes a homeobox
domain protein that is a likely nuclear transcription factor, which
is overexpressed in the presence of EWSR1-FLI1 fusions in
EWS tumors27,28. Our analysis did not detect signiﬁcant allele
speciﬁc expression differences for NKX2-2 in association with
rs6047482 (eQTL P-valueWald with rs12106193= 0.17, R2CEU and
D′CEU between rs6047482 and rs12106193= 0.67 and 1.00,
respectively)25. We explored eQTLs for other tissue types in
GTEx with surrogate SNPs in moderate to high linkage dis-
equilibrium with rs6047482, but found no evidence for an eQTL
with NKX2-2 in these tissues likely due to EWS speciﬁc expres-
sion of NKX2-2 (Supplementary Table 6)29. It is plausible that
EWSR1-FLI1-induced elevated NKX2-2 expression levels in EWS
cells hamper our ability to detect allele speciﬁc expression pat-
terns of NKX2-2 that may be important for EWS transformation
in the EWS progenitor cells. Further eQTL analyses in a large set
of mesenchymal stem cells, the suspected EWS cell-of-origin,
should enable this hypothesis to be tested. As with the 6p25.1
locus, ChIP-seq data show that EWSR1-FLI1 binds to one or
more polymorphic GGAA microsatellites proximal to the tagging
variants (Supplementary Figure 10) suggesting that variation in
this region could exert an effect through NKX2-2 gene regulation
in EWS progenitors and in turn through EWSR1-FLI1 binding
in EWS cells. Importantly, the six lead SNPs are on average
signiﬁcantly closer to EWSR1-FLI1 bound elements than
would be expected by chance on a chromosome-wide level
(P-valuesWilcoxon= 0.0025 and 0.0009 in A673 and TC71 cell
lines, respectively) (Supplementary Figure 8, Supplementary
Table 4).
Independent EWS susceptibility signal at 20p11. In the search
for additional independent loci at each EWS susceptibility locus
(Supplementary Figure 4), we identiﬁed a second, independent
signal on 20p11.23 tagged by rs6106336 based on a conditional
analysis using the discovery marker, rs6047482 (R2CEU= 0.003,
D′CEU= 0.23; OR= 1.74, 95% CI= 1.43–2.12, P-valuemeta=
2.33×10−8, P-valueconditional= 5.2×10−8, Fig. 2) with the G allele
acting as the risk associated allele. A distinct eQTL was observed
between a highly correlated surrogate for rs6106336, rs6047241
(R2CEU= 1.00, D′CEU= 1.00), and KIZ, kizuna centrosomal
protein, (also known as PLK1S1) with the risk G allele associated
with increased expression (P-valueWald= 0.01, Table 2). This
eQTL at 20p11.23 with KIZ does not appear to be restricted to
EWS and was observed in other GTEx tissues (e.g., artery, sun-
exposed skin, testis and whole blood; Supplementary Table 6).
KIZ localizes to the centrosomes and functions to strengthen and
stabilize the pericentriolar region prior to spindle formation30.
While limited evidence suggests EWSR1-FLI1 binding in this
region, H3K27ac patterns suggest areas of open chromatin that
may harbor variants important for regulation of nearby gene
products (Supplementary Figure 11).
EWS genetic risk score. In light of the observed set of EWS loci,
all with high estimated effect sizes, we generated a genetic risk
score (GRS) combining risk alleles from the six EWS suscept-
ibility loci to test the ability of an EWS GRS to discriminate
between EWS cases and cancer-free adult controls (Supplemen-
tary Figure 12). On average, EWS cases carried 1.08 more risk
alleles than controls (7.08 average risk alleles in EWS cases, 6.01
average risk alleles in controls; P-valueT-test= 2.44 × 10−63). Due
to the rarity of EWS and the relatively high frequency of these
common susceptibility alleles, absolute risks of EWS associated
with these six EWS susceptibility loci are low suggesting
population-based screening using these six variants is unlikely to
be effective.
Genetic architecture of EWS. Our new, expanded GWAS of
Ewing sarcoma has identiﬁed three new loci and also validated
the three previously reported susceptibility regions. In analyses of
the new loci, there is evidence of informative eQTLs with nearby
biologically plausible candidate genes that could be likely target
genes for future functional investigations. Additionally, EWSR1-
FLI1 ChIP-seq data suggest evidence for potential interactions of
germline variation at the 6p25.1 and 20p11.22 loci with the
EWSR1-FLI1 fusion protein as recently discovered at the 10q21
locus23. It is remarkable that six independent susceptibility
regions with relatively large effect sizes (estimated OR > 1.7) have
been discovered in a sample of 733 EWS cases. These results
provide a strong contrast to GWAS ﬁndings for the vast majority
of cancers that report estimated effect sizes less than 1.2. Inter-
estingly, GWAS in two highly heritable cancers (e.g., testicular
and thyroid)31,32 have also identiﬁed susceptibility alleles with
effect sizes in the range of what is observed for Ewing sarcoma.
The efﬁciency of our discovery as well as the higher estimated
EWS odds ratios could be related to the lack of tumor hetero-
geneity in our Ewing sarcoma GWAS, because most EWS cases
studied had a pathologically conﬁrmed EWSR1-ETS fusion, a
pathognomonic molecular feature of the EWS diagnosis. Fur-
thermore, our results suggest the underlying EWS genetic sus-
ceptibility architecture harbors a substantial number of moderate
effect common variants, which is striking because Ewing sarcoma
has not been considered to be highly heritable. In conclusion, our
study provides support for a strong inherited genetic component
to EWS risk and suggests interactions between germline variation
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and somatically acquired EWSR1-FLI1 translocations are
important etiologic contributors to EWS risk.
Methods
Study populations. EWS cases and controls for this GWAS originated from
several contributing studies. A set of published French EWS cases (N= 401) and
ancestry matched controls (N= 682) was extracted from the previously published
GWAS on EWS22. In addition, we combined a set of 122 French EWS cases from
the Institut Curie, 19 EWS cases from the National Cancer Institute (NCI) Center
for Cancer Research (CCR), 29 EWS cases from the NCI Bone Disease and Injury
Study33 along with 162 EWS cases from the Childhood Cancer Survivor Study
(CCSS)34,35. The SNPWEIGHTS software was used to calculate the percentage of
European ancestry using a set of population inference SNPs36,37. Only EWS cases
with >80% genetically estimated European ancestry were included in the analysis.
This resulted in a total of 749 EWS cases combined with 682 cancer-free controls
from the original EWS GWAS. To increase the sample size of available controls, we
identiﬁed a set of adult controls previously genotyped at the NCI Division of
Cancer Epidemiology and Genetics who were cancer-free at age 50, of European
ancestry and genotyped on a current generation of high-density Illumina geno-
typing platform. Controls originated from the Prostate Lung Colorectal and
Ovarian Cancer Screening Trial (N= 419), American Cancer Society Cancer
Prevention Study II (N= 171), and the Spanish Bladder Cancer Study (N= 74).
EWS cases without available controls were split into two groups: (1) the CCSS
group and (2) a Curie/NCI group that contained EWS cases from the Institute
Curie, NCI CCR and NCI Bone Disease and Injury Study. Principal component
matching was performed to identify ancestry matched controls for each EWS case
that were close genetic matches (Supplementary Figure 13). The ﬁrst three prin-
cipal components were used as matching factors and a 2:1 matching ratio of
controls to cases was carried out based on the availability of close control matches.
Matching was performed ﬁrst for the CCSS set to maximize matches with available
controls on high-density arrays. In total, our ﬁnal analysis set contained 733 EWS
cases and 1346 cancer-free controls.
All EWS cases were conﬁrmed by medical record review and the presence of a
speciﬁc EWSR1-ETS translocation were noted when data was available. Adult
controls were of European ancestry and cancer-free at time of DNA collection.
Each participant provided informed consent and each participating study was
approved by the Institutional Review Boards of their study center.
Genome-wide SNP genotyping and quality control assessment. Samples from
the previously published EWS GWAS22 were derived from bone marrow, blood or
tumor tissue. Genomic DNA was isolated using proteinase K lysis and phenol
chloroform extraction method. Genome-wide genotyping was performed on Illu-
mina 610 Quadv1 arrays at Integragen (Evry, France). For the CCSS EWS cases,
DNA was extracted using standard methods from blood, saliva (Oragene), or
buccal cells. For CCSS EWS cases with insufﬁcient DNA, whole genome ampliﬁ-
cation was performed38. Genotyping of CCSS EWS cases and quality control
replicates was conducted at the NCI Cancer Genomics Research Laboratory (CGR)
on the HumanOmni5Exome array. Genotypes were called using default parameters
in GenomeStudio (Illumina).
All de novo genotyping of EWS cases was performed at the NCI CGR on the
Illumina OmniExpress-24 v1.1 array. Genotyping was performed according to
manufacturer’s guidelines using the Inﬁnium HD Assay automated protocol. For
each sample, 400 ng of input DNA was denatured and neutralized then
isothermally ampliﬁed by whole-genome ampliﬁcation. The ampliﬁed product was
enzymatically fragmented, then precipitated and re-suspended before hybridization
to the BeadChip. Single-base extension of the oligos on the BeadChip, using the
captured DNA as a template, incorporated tagged nucleotides on the BeadChip,
which were subsequently ﬂuorophore labeled during staining. An Illumina iScan
scanned the BeadChips at two wavelengths to create image ﬁles. Genotypes were
called using default parameters in GenomeStudio. Standard quality control checks
were performed to ensure included EWS cases had high genotype completion rates
(≥95%), sex concordance, normal rates of heterozygosity and no unexpected
duplicates or cases of high relatedness (IBD < 0.1).
Missing genotypes were imputed in three sets: (1) the previously published
GWAS set22, (2) the CCSS EWS cases and matched controls and (3) the Curie/NCI
EWS cases and matched controls. For sets 2 and 3, only the common set of shared
genotypes between EWS cases and cancer-free controls was used as input for
imputation. All samples were ﬁrst phased using SHAPEIT39 and subsequently
imputed in IMPUTE240 using the 1000 Genomes Phase 3 release as the reference24.
Only SNPs with study info score greater than 0.3 and study minor allele counts
greater than or equal to 5 were carried on into the association analysis.
Statistical analysis. Association analyses were performed individually in each of
the three imputation sets using SNPTEST. Statistical adjustment was carried out for
principal components (PCs) used for matching (in the CCSS and Curie/NCI sets)
and those PCs signiﬁcantly associated with EWS risk. PCs were calculated in
PLINK41 using a set of population inference SNPs36. In the previously published
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Fig. 2 Conditional analysis at the 20p11.22-23 region. Overall meta-analysis –log10 P-values are plotted in gray in the background. In the foreground, meta-
analysis –log10 p-values when the top tagging SNP is the region (rs6047482) is conditioned on is plotted in blue. A second independent signal, tagged by
rs6106336, remains
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set, statistical adjustment was carried out for PC 2, PC 3, PC 6, PC 11 and PC 12. In
the CCSS set, PC 1, PC 2, PC 3, PC 5, PC 17 and PC 20 were adjusted for. For the
Curie/NCI set, statistical adjustment was carried out for PC 1, PC 2, PC 3, PC 4, PC
9, PC 15, PC 17 and PC 18.
Resulting statistical associations from each of the three sets were combined in
PLINK by ﬁxed effects meta-analysis. When performing the meta-analysis, beta
estimates and standard errors corresponded to the same reference alleles across all
three sets were merged. Resulting associations from the meta-analysis were ﬁltered
to include single nucleotide variants with minor allele frequency greater than 0.05
and P-values for Cochrane’s Q heterogeneity tests greater than 0.01.
Genetic risk scores (GRS) of the three previously discovered and three new
independent loci were calculated to investigate the ability of tagging variants from
these six loci to discriminate between EWS cases and controls. GRS were
constructed by summing the number of risk alleles an individual carried across all
six EWS loci. A T-test was used to assess statistical differences in mean risk alleles
carried in EWS cases as compared to controls. Area under the receiver operating
characteristic curve (AUC) was the metric used to measure discriminative ability of
the GRS.
Genotype validation. For each of the four newly discovered EWS loci, a top
genome-wide signiﬁcant SNP was genotyped by TaqMan in a subset of 335 samples
to validate signals from imputation. At each locus, genotyping was attempted for
the top associated SNP. When assay design failed for the top tagging SNP, the next
most highly SNP was sequentially attempted until an appropriate assay design was
established. The following SNPs were genotyped by TaqMan for each locus:
rs7744366 (6p25.1), rs7832583 (8q24.23), rs12106193 (20p11.23) and rs6106336
(20p11.23). Standard protocols were followed according to manufacturer’s guide-
lines when performing the TaqMan assays (Supplementary Table 7). Assays were
ﬁrst tested on HapMap samples to ensure validity before testing on EWS cases and
controls included in the GWAS.
Replication study. An independent set from the Institute Curie and European
collaborators consisting of 480 EWS cases and 576 controls and an independent
German set from LMU Munich containing 177 EWS cases and 3502 population-
based controls from the KORA S4 study were used as a replication sets to conﬁrm
associations at the 6p25.1, 8q24.23, 20p11.22 and 20p11.23 regions. The following
SNPs were genotyped by TaqMan for each locus: rs7744366 (6p25.1), rs7832583
(8q24.23), rs12106193 (20p11.23) and rs6106336 (20p11.23) (Supplementary
Table 7). Standard manufacturer’s protocols were followed when performing allele-
speciﬁc PCRs with these TaqMan assays. The 3502 German controls from the
KORA S4 cohort were genotyped with the Affymetrix Axiom array and imputed
using the 1000 Genomes phase 3 as well as the Haplotype Reference Consortium
(HRC) reference panels.
EWS functional data. All expression quantitative trait loci (eQTL) analyses were
performed using previously published expression data from 117 EWS samples22.
Samples were proﬁled using Affymetrix Human Genome U133 Plus 2.0 gene
expression arrays. Expression data are publically available at the Gene Expression
Omnibus (GEO) web portal (GSE34620). Affymetrix expression data were nor-
malized with the NormalizeBetweenArrays function of the LIMMA package
(http://web.mit.edu/~r/current/arch/i386_linux26/lib/R/library/limma/html/
normalizebetweenarrays.html). Wald tests of estimated betas from linear regression
models were performed to asses for allele speciﬁc differences in gene expression
levels.
Chromatin immunoprecipitation (ChIP). ChIP experiments were performed
following manufacture instructions using iDeal ChIP-seq kit for transcription
factors and for histones (Diagenode) with respectively a rabbit polyclonal anti-FLI1
antibody (Ab15289, Abcam) and a rabbit polyclonal anti-H3K27ac (Ab4729,
Abcam). The Ewing sarcoma A673 cell line was obtained from the American Type
Culture Collection (ATCC) and the Ewing sarcoma TC-71 cell line was obtained
from the German Collection of Microorganisms and Cell Cultures (DSMZ). STR-
proﬁling proved each cell line matched with the reference proﬁle provided by
ATCC and DSMZ, respectively; and cells were routinely tested for mycoplasma
contamination by PCR. Brieﬂy, the EWS cell lines were ﬁxed for 10 min with 1% of
methanol-free formaldehyde (28908, Thermo-Scientiﬁc). Chromatin was sonicated
(Bioruptor, Diagenode) for 20 cycles (30-sec on, 30-sec off) set at position “high” to
generate DNA fragments with an average size around 150–300pb. For ChIP
sequencing, the libraries were generated using TruSeq ChIP library preparation kit
(Illumina) and sequenced on Illumina HiSeq 2500 (single end, 100 bp). Reads were
aligned to hg19 reference genome with Bowtie242. Peaks were called with MACS243
with the option narrow for FLI1 ChIP-seq and broad for H3K27ac ChIP-seq. For
each cell line, ChIP-seq results were normalized according to their input sample.
Comparison of gene expression levels across cancer types. Publicly available
gene expression data for 19 different cancer entities comprising in total 616 tumor
samples, which were all proﬁled on Affymetrix Human Genome U133 Plus 2.0
gene expression arrays, were downloaded from the GEO or the Array Express
platform of the European Bioinformatics Institute (EBI) (accession codes:
GSE68015, GSE13433, GSE32569, GSE19404, GSE35493, GSE58697, GSE34620,
GSE34800, GSE60740, GSE19348, GSE17743, GSE8167, GSE53224, GSE16476, E-
MEXP-3628, GSE14827, GSE33458, E-TABM-1202, GSE29683, GSE20196,
GSE21050). Microarray data were simultaneously normalized using Robust Multi-
Chip Average (RMA)44 using brainarray CDF (v19 ENTREZG) yielding one
optimized probe-set per gene45.
Analysis of EWSR1-FLI1-modulated genes in vivo. For transcriptome-wide
analysis of EWSR1-FLI1-modulated genes 5 × 106 A673/TR/shEF1 cells46, which
contain a doxycycline (dox)-inducible shRNA against EWSR1-FLI1, were injected
subcutaneously in the ﬂanks of immunocompromised NSG (Nod scid gamma)
mice. A673/TR/shEF1 cells were authenticated by STR-proﬁling to match their
parental A673 cell line and were routinely tested for mycoplasma contamination by
PCR. When tumors reached an average volume of 180 mm3, mice were rando-
mized and either received 2 mg/l dox (Sigma) and 5% sucrose in the drinking water
(dox+) or only 5% sucrose (dox –). Mice were sacriﬁced 96 h after beginning of
dox-treatment, and tumors were collected for RNA and histological analysis. Total
RNA was extracted using the ReliaPrep miRNA Cell and Tissue Miniprep System
(Promega). Knock down of EWSR1-FLI1 was conﬁrmed by qRT-PCR as descri-
bed23, and proved to be downregulated onto 15% of the control (sucrose only).
Routine histology (H&E stains) of the tumors conﬁrmed high tumor purity
(>95%). The transcriptomes of 3 dox(+) and 3 dox (−) were proﬁled on Affy-
metrix Clariom D arrays (RIN > 9). Microarray data were simultaneously nor-
malized on gene level using Signal Space Transformation Robust Multi-Chip
Average (SST-RMA) and Affymetrix CDF. Animal experiments were conducted in
accordance with the recommendations of the European Community (86/609/EEC),
the Government of Upper Bavaria (Germany), and UKCCCR (guidelines for the
welfare and use of animals in cancer research). The sample size was not pre-
determined and no blinding was performed.
Data availability. Data from the newly genotyped individuals in EWS GWAS is
available on dbGaP under accession number phs001549.v1.p1 Data from CCSS is
available on dbGaP under accession number phs001327.v1.p1.
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